Sean A. Yamada‐Hunter
YOU?
Author Swipe
View article: 269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma Open
View article: CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA Open
H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal cancers in children and young adults. Our team previously demonstrated efficacy of GD2-targeting chimeric antigen receptor (GD2-CAR) T-cells in preclinical models of DMG …
View article: IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies Open
Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL). To identify tumor-intrinsic factors driving …
View article: IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia
IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia Open
Summary Relapse due to antigen escape is a major cause of treatment failure for patients with B-cell malignancies following targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor T (CAR T) cells. To identify …
View article: Engineered CD47 protects T cells for enhanced antitumour immunity
Engineered CD47 protects T cells for enhanced antitumour immunity Open
View article: Directed evolution of genetically encoded LYTACs for cell-mediated delivery
Directed evolution of genetically encoded LYTACs for cell-mediated delivery Open
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here, we pre…
View article: An engineered NKp46 antibody for construction of multi-specific NK cell engagers
An engineered NKp46 antibody for construction of multi-specific NK cell engagers Open
Recent developments in cancer immunotherapy have highlighted the potential of harnessing natural killer (NK) cells in the treatment of neoplastic malignancies. Of these, bispecific antibodies, and NK cell engager (NKCE) protein therapeutic…
View article: Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated Delivery
Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated Delivery Open
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here we pres…
View article: An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma
An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma Open
The cytokine interleukin (IL)‐11 has been shown to play a role in promoting fibrosis and cancer, including lung adenocarcinoma, garnering interest as an attractive target for therapeutic intervention. We used combinatorial methods to engin…
View article: Engineered CD47 protects T cells for enhanced antitumor immunity
Engineered CD47 protects T cells for enhanced antitumor immunity Open
Adoptively transferred T cells and agents designed to block the CD47/SIRPα axis are promising antitumor therapeutics, which activate distinct arms of the immune system. We administered anti-CD47 (αCD47) with adoptively transferred T cells …
View article: Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors Open
View article: An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy
An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy Open
View article: An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA Open
V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is an immune checkpoint that maintains peripheral T cell quiescence and inhibits anti-tumor immune responses. VISTA functions by dampening the interaction between myeloid…
View article: Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy
Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy Open
See related article by Viswanadhapalli et al., p. 1341Leukemia inhibitory factor (LIF) is a monomeric glycoprotein and belongs to the IL6 subfamily of the large "four-helix superfamily" of cytokines. LIF acts on responding cells by binding…
View article: Author Index
Author Index Open
View article: Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein
Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein Open
Dysregulated matriptase activity has been established as a key contributor to cancer progression through its activation of growth factors, including the hepatocyte growth factor (HGF). Despite its critical role and prevalence in many human…
View article: Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein Open
Dysregulated activity of the protease matriptase is a key contributor to aggressive tumor growth, cancer metastasis, and osteoarthritis. Methods for the detection and quantification of matriptase activity and inhibition would be useful too…
View article: Cell-Binding Assays for Determining the Affinity of Protein–Protein Interactions
Cell-Binding Assays for Determining the Affinity of Protein–Protein Interactions Open